SlideShare ist ein Scribd-Unternehmen logo
1 von 19
RAJESHWAREE NETHA
Doctor of Pharmacy
Contents
Introduction
Pathophysiology
Clinical presentation
Treatment
General approach
Pharmacologic therapy
Evaluation of therapeutic outcomes
INTRODUCTION
•Obesity occurs when there is an imbalance
between energy intake and energy
expenditure overtime, resulting in
increased energy storage.
PATHOPHYSIOLOGY:
•The etiology of obesity usually unknown,
but it is likely multifactorial and related to
Varying contributions from genetic,
environmental, and physiological factors.
•Genetic factors appears to be the primary
determinants of obesity in some individuals ,where
as environmental factors are more important in
others.
•Identification of the total no. of contributing genes
is an area of extensive research.
•Environmental factors include reduced physical
activity or work ,abundant food supply , relatively
sedentary environmental factors are more import
lifestyles, increased availability of high fat foods,
and cultural factors and religious beliefs.
•Medical conditions including Cushing disease and
growth hormone deficiency or
•Condition such as Prader-Willi syndrome can be
associated with weight gain.
•Medication associated with weight gain include
insulin, corticosteroids, some anti depressants,
antipsychotics, and several anti convulsants.
•Many neurotransmitters and neuropeptides
stimulate or depress the brain's appetite
Network, impacting total calorie intake.
•The degree of obesity is determined by the net
balance of energy ingested relative to energy
expended overtime.
•The single largest determinant of energy
expenditure is
Metabolic rate, which is expressed as resting
energy expenditure or basal metabolic rate.
•Physical activity is the other major factor that
affects total energy expenditure.
•Major types of adipose tissue are (1)white adipose
tissue, which manufactures
stores, and release lipid ,and (2)brown adipose
tissue, which dissipates energy via uncoupled
mitochondrial respiration.
•Adrenergic stimulation activates lipolysis in fat
Cells and increases energy expenditure in
adipose tissue and skeletal muscle.
CLINICAL PRESENTATIONS:
•Obesity is associated with serious health risks
and increased mortality.
•Central Obesity reflects high levels of intra
abdominal or visceral fat that is associated with
the development of HTN, dyslipidemia, and
cardiovascular diseases.
•Other obesity co morbidities are osteoarthritis
and changes in the female Reproductive system.
•Body mass index (BMI) and waist circumference
(WC) are recognized, acceptable Markers of
excess body fat that independently predict
disease risk .
•BMI is calculated as weight (kg) divided by the
square of the height (m2).
•WC, the most practical method of characterizing
central adiposity, is the narrowest circumference
between the last rib and the top of the lilac crest.
TREATMENT
•Goals of treatment: Weight management goals
may include losing a predefined amount of
weight, decreasing the rate of weight gain ,or
maintaining a weight-neutral status depending on
the clinical situation.
GENERAL APPROACH
•Successful obesity treatment plans incorporate
reduced caloric intake ,exercise ,behavioral
modifications with or without pharmacological the
therapy and / or surgery.
•Weight loss of 5 to 10% of initial weight
is are reasonable goal for obesity patients.
•Measures of success not only include pound
lost but also improvement in co morbid
Conditions including blood pressure, blood
glucose, and lipids.
•Many diets exits to aid weight loss. Regardless
of program energy consumption must be less
than energy expenditure.
•A reasonable goal is loss of o.1 to 5 kg per
week with a balanced diet in fat, carbydrate, and
Protein intake.
•Increased physical activity combined with reduced
calorie intake and behavior modification can
augment weight loss and improve obesity-related
co morbidities and cardio vascular risk factors.
•The primary aim of behavior modification is to
help patients choose life styles conductive to
Safe and sustained weight loss.
•Behavioral therapy of human learning which use
stimulus control and Reinforcement to substitute
desirable behavioral for learned, undesirable
habits.
•Bariatric surgery, which reduces the stomach
volume or absorptive surface of the alimentary
tract ,remains the most effective intervention for
obesity.
•Surgery should be reserved for those with BMI
above 35 or 40kg/m and significant co
morbidities due to the morbidity and mortality
associated with the surgical procedures.
PHARMACOLOGICAL THERAPY
•The debate regarding the role of
pharmacotherapy remains heated, fueled by the
need to treat to growing epidemic and by the
fallout from the removal of several agents from
the market because of adverse reactions.
•Long term pharmacotherapy have a role for
patients who have no contraindications to
approved Drug therapy.
•The National institutes of Heath Guidelines
recommend consideration of pharmacotherapy in
adults with BMI 230kg/m2 and /or W C<40 in
(102cm) for men or 35 in (9cm ) for women ,or
BMI of 10 to 30 kg/m2 with least two concurrent
factors if 6 months of diet exercise and
behavioral modification failed to achieve weight
loss.
•Orlistat (180 or 60 mg in 3 divided doses/day) is
a lipase inhibitor that induces weight loss by
lowering dietary fat absorption.
•It also improves lipid profiles, glucose
Control and other metabolic markers.
•Soft stools, abdominal pain or colic
flatulence, and/or incontinence occur in 80%
of individual using prescription strength are
mild to moderate in severity and improve
after 1to2 months of therapy.
•ORLISTAT is approved for long-term use .It
interferes with the absorption of fat-soluble
vitamins, cyclosporine , levothyroxine , and
oral contraceptives.
•LORCASERIN is a selective serotonin receptor
agonist (5-HT,) approved for chronic weight
management.
•Activation of central5-HT, receptors results in
appetite suppression leading to modest weight loss
as compared with placebo.
•Discontinue lorscaserin if 5% weight loss is not
achieved by week 12.
•Common adverse effects include dizziness,
constipation, fatigue, and dry mouth.
•Phentermine and diethylpropion are each more
effective than placebo in achieving short weight
loss.
•Neither should be used in patients with severe
hypertension or significant cardiovascular disease.
•Short-term therapy is not consistent with current
national
guidelines for chronic management of obesity.
•Amphetamines should generally be avoided
because of their powerful stimulant effects and
additive potential.
•Many complementary and alternative products are
promoted to weight loss.
•Regulation of dietary supplements are less
rigorous than that of prescription and over the
counter drug products, manufacturers do not have
to prove safety and effectiveness prior to
marketing.
•EVALUATION THERAPEUTIC OUTCOMES
•Assess progress once or twice monthly for 1or2
months, then monthly.
•Each encounter should document weight, WC,BMI,
blood pressure, medical history ,and patient
assessment of tolerability of drug therapy.
•Discontinue mediation therapy for 3to4 months if
the patient has failed to demonstrate weightloss or
maintenance of prior weight.
•Diabetic patients require more intense medical
monitoring and self-monitoring of blood glucose.
• Weekly health care visits for 1to2 months may be
necessary until the effects of diet, exercise, and
weight loss medication become more predictable.
•Monitor patients with hyperlipidemia or
hypertension to assess effects of weight loss on
appropriate end points.
Obesity

Weitere ähnliche Inhalte

Was ist angesagt? (20)

Present management of obesity in adult
Present management of obesity in adultPresent management of obesity in adult
Present management of obesity in adult
 
Presentation obesity
Presentation obesityPresentation obesity
Presentation obesity
 
MNT in chronic renal failure
MNT in chronic renal failureMNT in chronic renal failure
MNT in chronic renal failure
 
Diet and Cancer
Diet and CancerDiet and Cancer
Diet and Cancer
 
Hypertension and Cardiovascular Disease Clinical Nutrition Case Study
Hypertension and Cardiovascular Disease Clinical Nutrition Case StudyHypertension and Cardiovascular Disease Clinical Nutrition Case Study
Hypertension and Cardiovascular Disease Clinical Nutrition Case Study
 
Celiac disease diet mgmt
Celiac disease diet mgmtCeliac disease diet mgmt
Celiac disease diet mgmt
 
Obesity
ObesityObesity
Obesity
 
OBESITY
OBESITYOBESITY
OBESITY
 
Obesity
ObesityObesity
Obesity
 
Obesity
ObesityObesity
Obesity
 
Obesity
ObesityObesity
Obesity
 
Pre Diabetes
Pre Diabetes Pre Diabetes
Pre Diabetes
 
Obesity2
Obesity2Obesity2
Obesity2
 
Obesity
ObesityObesity
Obesity
 
Obesity
ObesityObesity
Obesity
 
Orlistat
OrlistatOrlistat
Orlistat
 
Clinical assessment tools in hospitals
Clinical assessment tools in hospitalsClinical assessment tools in hospitals
Clinical assessment tools in hospitals
 
Stroke and Nutrition - Dr. Krizia Ferrini
Stroke and Nutrition - Dr. Krizia FerriniStroke and Nutrition - Dr. Krizia Ferrini
Stroke and Nutrition - Dr. Krizia Ferrini
 
Cancer (Diet therapy, Nutritional care)
Cancer (Diet therapy, Nutritional care)Cancer (Diet therapy, Nutritional care)
Cancer (Diet therapy, Nutritional care)
 
OBESITY
OBESITYOBESITY
OBESITY
 

Ähnlich wie Obesity

Obesity and metabolic syndrome.pptx
Obesity and metabolic syndrome.pptxObesity and metabolic syndrome.pptx
Obesity and metabolic syndrome.pptxjyoti verma
 
Medical Management of Severe Eating Disorders
Medical Management of Severe Eating DisordersMedical Management of Severe Eating Disorders
Medical Management of Severe Eating DisordersThe Doctor Weighs In
 
Drug treatment of obesity
Drug treatment of obesityDrug treatment of obesity
Drug treatment of obesityamit7887
 
GIT j club obesity trts.
GIT j club obesity trts.GIT j club obesity trts.
GIT j club obesity trts.Shaikhani.
 
Recent Advances in Obesity Pharmacotherapy
Recent Advances in Obesity PharmacotherapyRecent Advances in Obesity Pharmacotherapy
Recent Advances in Obesity PharmacotherapyShreya Gupta
 
Obesity dr njeru
Obesity dr njeruObesity dr njeru
Obesity dr njeruAhmedaedy
 
Session 2: Chronic disease prevention and management in primary care settings
Session 2: Chronic disease prevention and management in primary care settingsSession 2: Chronic disease prevention and management in primary care settings
Session 2: Chronic disease prevention and management in primary care settingsWHO Regional Office for Europe
 
Metabolic syndrome,obesity
Metabolic syndrome,obesityMetabolic syndrome,obesity
Metabolic syndrome,obesityAli Yousafzai
 
Session 7: Advise on health risks of obesity and treatment options
Session 7: Advise on health risks of obesity and treatment optionsSession 7: Advise on health risks of obesity and treatment options
Session 7: Advise on health risks of obesity and treatment optionsWHO Regional Office for Europe
 
Nutrition in head and neck cancer
Nutrition in head and neck cancerNutrition in head and neck cancer
Nutrition in head and neck cancerSREENIVAS KAMATH
 
Dr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdf
Dr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdfDr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdf
Dr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdfMahsaSpecialistHospi
 
Obesity and principles of metabolic surgery
Obesity and principles of metabolic surgeryObesity and principles of metabolic surgery
Obesity and principles of metabolic surgeryUday Sankar Reddy
 
obesity managment by Faris Hakami.pptx
obesity managment by Faris Hakami.pptxobesity managment by Faris Hakami.pptx
obesity managment by Faris Hakami.pptxssuser08c90e1
 
Diet counselling for obesitty
Diet counselling for obesittyDiet counselling for obesitty
Diet counselling for obesittyiqra ejaz
 
nutrition, obesity and body weight regulation
nutrition, obesity and body weight regulationnutrition, obesity and body weight regulation
nutrition, obesity and body weight regulationDrQamarYasmeen
 

Ähnlich wie Obesity (20)

Obesity and metabolic syndrome.pptx
Obesity and metabolic syndrome.pptxObesity and metabolic syndrome.pptx
Obesity and metabolic syndrome.pptx
 
Medical Management of Severe Eating Disorders
Medical Management of Severe Eating DisordersMedical Management of Severe Eating Disorders
Medical Management of Severe Eating Disorders
 
Drug treatment of obesity
Drug treatment of obesityDrug treatment of obesity
Drug treatment of obesity
 
obesity - a systematic approach
obesity - a systematic approachobesity - a systematic approach
obesity - a systematic approach
 
GIT j club obesity trts.
GIT j club obesity trts.GIT j club obesity trts.
GIT j club obesity trts.
 
Recent Advances in Obesity Pharmacotherapy
Recent Advances in Obesity PharmacotherapyRecent Advances in Obesity Pharmacotherapy
Recent Advances in Obesity Pharmacotherapy
 
Obesity dr njeru
Obesity dr njeruObesity dr njeru
Obesity dr njeru
 
Session 2: Chronic disease prevention and management in primary care settings
Session 2: Chronic disease prevention and management in primary care settingsSession 2: Chronic disease prevention and management in primary care settings
Session 2: Chronic disease prevention and management in primary care settings
 
Obesity
Obesity Obesity
Obesity
 
Obesity
Obesity Obesity
Obesity
 
Metabolic syndrome,obesity
Metabolic syndrome,obesityMetabolic syndrome,obesity
Metabolic syndrome,obesity
 
Session 7: Advise on health risks of obesity and treatment options
Session 7: Advise on health risks of obesity and treatment optionsSession 7: Advise on health risks of obesity and treatment options
Session 7: Advise on health risks of obesity and treatment options
 
Git j club obesity mdt approach22
Git j club obesity mdt approach22Git j club obesity mdt approach22
Git j club obesity mdt approach22
 
Nutrition in head and neck cancer
Nutrition in head and neck cancerNutrition in head and neck cancer
Nutrition in head and neck cancer
 
Dr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdf
Dr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdfDr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdf
Dr Dato Anitha Haniffa - Understanding Bariatric Surgery.pdf
 
Bariatric surgery
Bariatric surgeryBariatric surgery
Bariatric surgery
 
Obesity and principles of metabolic surgery
Obesity and principles of metabolic surgeryObesity and principles of metabolic surgery
Obesity and principles of metabolic surgery
 
obesity managment by Faris Hakami.pptx
obesity managment by Faris Hakami.pptxobesity managment by Faris Hakami.pptx
obesity managment by Faris Hakami.pptx
 
Diet counselling for obesitty
Diet counselling for obesittyDiet counselling for obesitty
Diet counselling for obesitty
 
nutrition, obesity and body weight regulation
nutrition, obesity and body weight regulationnutrition, obesity and body weight regulation
nutrition, obesity and body weight regulation
 

Mehr von Rajeshwari Netha

DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....
DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....
DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....Rajeshwari Netha
 
Antimicrobials - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...
Antimicrobials  - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...Antimicrobials  - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...
Antimicrobials - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...Rajeshwari Netha
 
Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...
Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...
Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...Rajeshwari Netha
 
Routes of administration...pharmacology
Routes of administration...pharmacologyRoutes of administration...pharmacology
Routes of administration...pharmacologyRajeshwari Netha
 
Chromatin, types and functions of chromatin
Chromatin, types and functions of chromatinChromatin, types and functions of chromatin
Chromatin, types and functions of chromatinRajeshwari Netha
 
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.Rajeshwari Netha
 

Mehr von Rajeshwari Netha (10)

DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....
DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....
DOCTOR OF PHARMACT (Pharm D) SIX YEARS OSMANIA UNIVERSITY .....SYLLABUS .....
 
Antimicrobials - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...
Antimicrobials  - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...Antimicrobials  - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...
Antimicrobials - AMINOGLYCOSIDES, AMPHOTERICIN, CEPHALOSPORINS, CHLORAMPHENI...
 
Dbms.....SQL statemets
Dbms.....SQL statemetsDbms.....SQL statemets
Dbms.....SQL statemets
 
Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...
Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...
Thyroid pharmacotherapeutics - definition, aetiology, clinical manifestations...
 
Routes of administration...pharmacology
Routes of administration...pharmacologyRoutes of administration...pharmacology
Routes of administration...pharmacology
 
Chromatin, types and functions of chromatin
Chromatin, types and functions of chromatinChromatin, types and functions of chromatin
Chromatin, types and functions of chromatin
 
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
PRESENTATION ON PARKINSONISM - A DISORDER OF CENTRAL NERVOUS SYSTEM.
 
plant growth regulators
plant growth regulatorsplant growth regulators
plant growth regulators
 
case presentation on cOPD
case presentation on cOPDcase presentation on cOPD
case presentation on cOPD
 
Dyslipidemia
DyslipidemiaDyslipidemia
Dyslipidemia
 

Kürzlich hochgeladen

Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfAyushMahapatra5
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesShubhangi Sonawane
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Shubhangi Sonawane
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIShubhangi Sonawane
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhikauryashika82
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 

Kürzlich hochgeladen (20)

Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Asian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptxAsian American Pacific Islander Month DDSD 2024.pptx
Asian American Pacific Islander Month DDSD 2024.pptx
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural ResourcesEnergy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
Energy Resources. ( B. Pharmacy, 1st Year, Sem-II) Natural Resources
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 

Obesity

  • 3. INTRODUCTION •Obesity occurs when there is an imbalance between energy intake and energy expenditure overtime, resulting in increased energy storage. PATHOPHYSIOLOGY: •The etiology of obesity usually unknown, but it is likely multifactorial and related to Varying contributions from genetic, environmental, and physiological factors.
  • 4. •Genetic factors appears to be the primary determinants of obesity in some individuals ,where as environmental factors are more important in others. •Identification of the total no. of contributing genes is an area of extensive research. •Environmental factors include reduced physical activity or work ,abundant food supply , relatively sedentary environmental factors are more import lifestyles, increased availability of high fat foods, and cultural factors and religious beliefs. •Medical conditions including Cushing disease and growth hormone deficiency or •Condition such as Prader-Willi syndrome can be associated with weight gain.
  • 5. •Medication associated with weight gain include insulin, corticosteroids, some anti depressants, antipsychotics, and several anti convulsants. •Many neurotransmitters and neuropeptides stimulate or depress the brain's appetite Network, impacting total calorie intake. •The degree of obesity is determined by the net balance of energy ingested relative to energy expended overtime.
  • 6. •The single largest determinant of energy expenditure is Metabolic rate, which is expressed as resting energy expenditure or basal metabolic rate. •Physical activity is the other major factor that affects total energy expenditure. •Major types of adipose tissue are (1)white adipose tissue, which manufactures stores, and release lipid ,and (2)brown adipose tissue, which dissipates energy via uncoupled mitochondrial respiration.
  • 7. •Adrenergic stimulation activates lipolysis in fat Cells and increases energy expenditure in adipose tissue and skeletal muscle. CLINICAL PRESENTATIONS: •Obesity is associated with serious health risks and increased mortality. •Central Obesity reflects high levels of intra abdominal or visceral fat that is associated with the development of HTN, dyslipidemia, and cardiovascular diseases.
  • 8. •Other obesity co morbidities are osteoarthritis and changes in the female Reproductive system. •Body mass index (BMI) and waist circumference (WC) are recognized, acceptable Markers of excess body fat that independently predict disease risk . •BMI is calculated as weight (kg) divided by the square of the height (m2). •WC, the most practical method of characterizing central adiposity, is the narrowest circumference between the last rib and the top of the lilac crest.
  • 9. TREATMENT •Goals of treatment: Weight management goals may include losing a predefined amount of weight, decreasing the rate of weight gain ,or maintaining a weight-neutral status depending on the clinical situation. GENERAL APPROACH •Successful obesity treatment plans incorporate reduced caloric intake ,exercise ,behavioral modifications with or without pharmacological the therapy and / or surgery.
  • 10. •Weight loss of 5 to 10% of initial weight is are reasonable goal for obesity patients. •Measures of success not only include pound lost but also improvement in co morbid Conditions including blood pressure, blood glucose, and lipids. •Many diets exits to aid weight loss. Regardless of program energy consumption must be less than energy expenditure. •A reasonable goal is loss of o.1 to 5 kg per week with a balanced diet in fat, carbydrate, and Protein intake.
  • 11. •Increased physical activity combined with reduced calorie intake and behavior modification can augment weight loss and improve obesity-related co morbidities and cardio vascular risk factors. •The primary aim of behavior modification is to help patients choose life styles conductive to Safe and sustained weight loss. •Behavioral therapy of human learning which use stimulus control and Reinforcement to substitute desirable behavioral for learned, undesirable habits.
  • 12. •Bariatric surgery, which reduces the stomach volume or absorptive surface of the alimentary tract ,remains the most effective intervention for obesity. •Surgery should be reserved for those with BMI above 35 or 40kg/m and significant co morbidities due to the morbidity and mortality associated with the surgical procedures. PHARMACOLOGICAL THERAPY •The debate regarding the role of pharmacotherapy remains heated, fueled by the need to treat to growing epidemic and by the fallout from the removal of several agents from the market because of adverse reactions.
  • 13. •Long term pharmacotherapy have a role for patients who have no contraindications to approved Drug therapy. •The National institutes of Heath Guidelines recommend consideration of pharmacotherapy in adults with BMI 230kg/m2 and /or W C<40 in (102cm) for men or 35 in (9cm ) for women ,or BMI of 10 to 30 kg/m2 with least two concurrent factors if 6 months of diet exercise and behavioral modification failed to achieve weight loss. •Orlistat (180 or 60 mg in 3 divided doses/day) is a lipase inhibitor that induces weight loss by lowering dietary fat absorption.
  • 14. •It also improves lipid profiles, glucose Control and other metabolic markers. •Soft stools, abdominal pain or colic flatulence, and/or incontinence occur in 80% of individual using prescription strength are mild to moderate in severity and improve after 1to2 months of therapy. •ORLISTAT is approved for long-term use .It interferes with the absorption of fat-soluble vitamins, cyclosporine , levothyroxine , and oral contraceptives.
  • 15. •LORCASERIN is a selective serotonin receptor agonist (5-HT,) approved for chronic weight management. •Activation of central5-HT, receptors results in appetite suppression leading to modest weight loss as compared with placebo. •Discontinue lorscaserin if 5% weight loss is not achieved by week 12. •Common adverse effects include dizziness, constipation, fatigue, and dry mouth.
  • 16. •Phentermine and diethylpropion are each more effective than placebo in achieving short weight loss. •Neither should be used in patients with severe hypertension or significant cardiovascular disease. •Short-term therapy is not consistent with current national guidelines for chronic management of obesity. •Amphetamines should generally be avoided because of their powerful stimulant effects and additive potential. •Many complementary and alternative products are promoted to weight loss.
  • 17. •Regulation of dietary supplements are less rigorous than that of prescription and over the counter drug products, manufacturers do not have to prove safety and effectiveness prior to marketing. •EVALUATION THERAPEUTIC OUTCOMES •Assess progress once or twice monthly for 1or2 months, then monthly. •Each encounter should document weight, WC,BMI, blood pressure, medical history ,and patient assessment of tolerability of drug therapy.
  • 18. •Discontinue mediation therapy for 3to4 months if the patient has failed to demonstrate weightloss or maintenance of prior weight. •Diabetic patients require more intense medical monitoring and self-monitoring of blood glucose. • Weekly health care visits for 1to2 months may be necessary until the effects of diet, exercise, and weight loss medication become more predictable. •Monitor patients with hyperlipidemia or hypertension to assess effects of weight loss on appropriate end points.